Related Resources
certis-logo-lockup_vertical-RGB

CLIA-Certified

About Us

Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Oncology Intelligence™ — highly predictive therapeutic response data derived from advanced biological models of cancer. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies.

We partner with therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Certis brings greater certainty to go/no-go development decisions through more clinically relevant, well-characterized and annotated models combined with advanced imaging technology. Every preclinical study Certis designs with you is rooted in collaboration, scientific resolve, a bias for precision and a close connection to the patient.

REFERENCES: 1 Patrizii M, Bartucci M, Pine SR, Sabaawy HE. Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol. 2018;8:23. 2 Joo KM, Kim J, Jin J, et al. Patient-Specific Orthotopic Glioblastoma Xenograft Models Recapitulate the Histopathology and Biology of Human Glioblastomas In Situ. Cell Rep. 2013;3(1):260-273.] 3 Baumann BC, Dorsey JF, Benci JL et al. Stereotactic Intracranial Implantation and In Vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme. J Vis Exp. 2012;(67):4089. 4 Rajan RG, Fernandez-Vega V, Sperry J, Nakashima J, Do LH, Andrews W, Boca S, Islam R, Chowdhary SA, Seldin J, et al. In Vitro and In Vivo Drug-Response Profiling Using Patient-Derived High-Grade Glioma. Cancers. 2023; 15(13):3289.